$KRRO

Vincent Loic A sold $37K of KRRO

Vincent Loic A (Chief Scientific Officer) sold 3,418 shares of Korro Bio, Inc. (KRRO) at $10.83 on 2026-06-16.

Original reporting
SEC EDGAR · Vincent Loic A
Published Jun 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
medium confidence
Mentioned
$KRRO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by the CSO.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide new operational or financial guidance.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on compensation, tax liabilities, or prior sale patterns.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-17, sale dated 2026-06-16

Background

The article is a SEC Form 4 insider transaction report for Korro Bio, Inc.

Company-level read

Ticker impact

$KRRONeutralMedium confidence
Context

Korro Bio CSO Vincent Loic A filed a Form 4 open-market sale of 3,418 shares at $10.83 on 2026-06-16.

Expected impact

Likely limited, with any impact confined to short-term sentiment rather than fundamentals.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying operational or guidance change disclosed in the text.

Market effects

Minimal, as the disclosure does not indicate sector-wide regulatory, clinical, or financing developments.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or tax needs, so the signal may be weaker than it appears.

Key entities

  • Korro Bio, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Vincent Loic A

    Chief Scientific Officer who sold 3,418 shares.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria